Business Combination (Details) - LymphaTech - USD ($) $ in Thousands |
6 Months Ended | |
|---|---|---|
Feb. 17, 2026 |
Jun. 30, 2026 |
|
| Asset Acquisition | ||
| Total purchase consideration | $ 7,230 | |
| Sellers' transaction expenses | 200 | $ 800 |
| Estimated fair value of contingent consideration | $ 4,863 | |
| Fair value adjustments | $ 0 |
| X | ||||||||||
- Definition Amount of contingent consideration recognized as part of consideration transferred in a business combination. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for acquisition-related cost incurred to effect business combination. Includes, but is not limited to, finder's fee; advisory, legal, accounting, valuation, and other professional and consulting fees; and general administrative cost, including cost of maintaining internal acquisition department. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|